Utpal Koppikar
Net Worth
Last updated:
What is Utpal Koppikar net worth?
The estimated net worth of Mr. Utpal Koppikar is at least $7,137,255 as of 2 Mar 2023. He owns shares worth $2,183,718 as insider, has earned $365,387 from insider trading and has received compensation worth at least $4,588,150 in Atara Biotherapeutics, Inc..
What is the salary of Utpal Koppikar?
Mr. Utpal Koppikar salary is $655,450 per year as Chief Financial Officer & SVice President in Atara Biotherapeutics, Inc..
How old is Utpal Koppikar?
Mr. Utpal Koppikar is 54 years old, born in 1971.
What stocks does Utpal Koppikar currently own?
As insider, Mr. Utpal Koppikar owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | Chief Financial Officer & SVice President | 181,978 | $12 | $2,183,718 |
What does Atara Biotherapeutics, Inc. do?
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Utpal Koppikar insider trading
Atara Biotherapeutics, Inc.
Mr. Utpal Koppikar has made 24 insider trades between 2018-2023, according to the Form 4 filled with the SEC. Most recently he sold 6,871 units of ATRA stock worth $24,921 on 2 Mar 2023.
The largest trade he's ever made was exercising 6,871 units of ATRA stock on 2 Mar 2023. As of 2 Mar 2023 he still owns at least 181,978 units of ATRA stock.